A Specialty Life Sciences Company

Corporate Presentation
June 2020
Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.
REVIVE THERAPEUTICS

- Specialty life sciences company focused on repurposing drugs for rare disorders and infectious diseases

- Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (Phase 3)

- Developing novel Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders

- Robust patent portfolio covering methods and compositions of drugs

- Significantly undervalued compared to its peers
Clinical development of Psilocybin, Cannabidiol and Bucillamine

Targeting Rare Disorders and Infectious Diseases

Novel Uses, Formulations, and Delivery System

Targeting FDA Designations: Orphan, Fast track, Breakthrough therapy and Rare pediatric diseases
<table>
<thead>
<tr>
<th>Title</th>
<th>USPTO No.</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19</td>
<td>62/991,996</td>
<td>Provisional patent filed</td>
</tr>
<tr>
<td>Use of Bucillamine in the Treatment of Gout</td>
<td>US 9662305</td>
<td>Issued on May 30, 2017</td>
</tr>
<tr>
<td>Psilocybin effervescent and psilocybin tablet - Solid Oral Pharmaceutical Compositions</td>
<td>62/985,052</td>
<td>Provisional patent filed</td>
</tr>
<tr>
<td>Psilocybin hard-shell capsules - Pharmaceutical Capsule Compositions</td>
<td>62/985,070</td>
<td>Provisional patent filed</td>
</tr>
<tr>
<td>Psilocybin gum drops - Pharmaceutical Gumdrop Compositions</td>
<td>62/985,084</td>
<td>Provisional patent filed</td>
</tr>
<tr>
<td>Psilocybin oral strips and transmucosal - Thin-Film Pharmaceutical Delivery System and Formulations</td>
<td>62/985,098</td>
<td>Provisional patent filed</td>
</tr>
<tr>
<td>Psilocybin - Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration</td>
<td>62/984,590</td>
<td>Provisional patent filed</td>
</tr>
<tr>
<td>Methods for the Extraction and Crystallization of Psilocybin</td>
<td>62/985,360</td>
<td>Provisional patent filed</td>
</tr>
<tr>
<td>Use of Cannabidiol in the Treatment of Autoimmune Hepatitis</td>
<td>US 8242178</td>
<td>Issued on August 14, 2012</td>
</tr>
<tr>
<td>Product</td>
<td>Indication</td>
<td>Stage of Development</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Bucillamine</td>
<td>Infectious Diseases (COVID-19)</td>
<td>Filing IND</td>
</tr>
<tr>
<td>Psilocybin</td>
<td>Undisclosed</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Psilocybin</td>
<td>Undisclosed Multiple Indications</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>CBD</td>
<td>Liver Diseases (Autoimmune Hepatitis)</td>
<td>Filing IND</td>
</tr>
</tbody>
</table>
Focus on Bucillamine in the treatment of infectious diseases
- Well-known safety profile and prescribed for arthritis in Japan and South Korea for over 30 years

Revive’s clinical history with Bucillamine
- Obtained 2 FDA INDs with Bucillamine and FDA orphan drug status
- FDA Phase 2 clinical study for acute gout flares and cystinuria

Bucillamine (BUC) scientific rationale as an intervention for COVID-19 (see Appendix)
- BUC is 16x more potent than particularly N-acetylcysteine (NAC); NAC has shown to prevent acute lung injury caused by influenza virus
- BUC shown superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection
- BUC also shown to prevent oxidative and reperfusion injury in heart and liver tissues
- BUC proven safety and MOA similar to NAC, but with much higher potency

Advancing towards FDA Phase 3 clinical study for COVID-19
PSYCHEDELIC OPPORTUNITY

- **Acquired Psilocin Pharma Corp.**
  - Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis
  - Worked with Xanthic Bio Pharma and Green Growth Brands
  - Developed water Soluble THC and CBD products (Beverages, effervescent tablets)

- **Novel Psilocybin formulations, extraction and purification methods**
  - Suited for pharmaceutical development and recreational markets where legal

- **Patent pending Psilocybin formulations (natural synthetic derived)**
  - Capsules, Sublingual Spray, Gel Cap, Effervescent Tablets, and Oral Strips

- **Targeting rare diseases, mental health and addiction**
Delivering naturally extracted and synthetic psilocybin and cannabinoids

**PSILOCYBIN** - Precise dosed formulations i.e. capsules, sublingual spray, gel caps, effervescent tablets and oral/transmucosal strips

- Releases (rapid, controlled, sustained), improved bioavailability, no first-pass metabolism

**CANNABIDIOL** - Novel combination of composites allowing for multiple delivery formats, potential synergistic and therapeutic effects

- **Tannin** (plant-based) - antibacterial, antifungal, antioxidant and wound healing
- **Chitosan** (shrimp-based) - blood-clotting and antimicrobial properties
Focus on Autoimmune Hepatitis (AIH)

AIH - rare disease (~ 76k patients in US) causing liver inflammation
- Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug withdrawal in 50%-86%*

Obtained FDA orphan drug status for CBD in the treatment of AIH

Seeking to file FDA IND to conduct Phase 2 clinical study in patient affected by AIH

Big Pharma interest in liver diseases
- Allergan acquisition of Tobira for $1.7 billion
- Novartis license of Conatus drug for $650 million
- Gilead acquisition of Nimbus for $1.2 billion

STRATEGIC PARTNERS

Infectious Diseases CRO

Acquired March 2020
Psychedelic pharma

R&D partnership
Psychedelic pharma

Supply and collaboration of truffles

License of cannabidiol for treatment of Autoimmune Hepatitis

License of cannabinoid delivery technology

Research collaboration for liver diseases
<table>
<thead>
<tr>
<th>Quarter</th>
<th>Milestone Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2</td>
<td>Submit FDA IND for Phase 3 clinical study of Bucillamine in the treatment of COVID-19</td>
</tr>
<tr>
<td>Q3</td>
<td>Initiate Phase 3 clinical study of Bucillamine in the treatment of COVID-19 in the U.S.</td>
</tr>
<tr>
<td>Q3</td>
<td>Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)</td>
</tr>
<tr>
<td>Q3</td>
<td>Pre-IND meeting with FDA for Psilocybin (undisclosed indications)</td>
</tr>
<tr>
<td>Q3</td>
<td>Patient enrollment / dosing of Phase 3 study of Bucillamine in the treatment of COVID-19</td>
</tr>
<tr>
<td>Q4</td>
<td>Initial results from Phase 3 clinical study of Bucillamine in the treatment of COVID-19</td>
</tr>
<tr>
<td>Q4</td>
<td>Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis</td>
</tr>
<tr>
<td>Q4</td>
<td>Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)</td>
</tr>
</tbody>
</table>
Peer Comparison (*Market Caps*)

- **GW Pharmaceuticals**: $3.7 Billion
- **Champignon Brands**: $155 Million
- **MindMed**: $155 Million
- **Arch Biopartners**: $90 Million
- **Revive Therapeutics**: $37 Million
ORGANIZATION

Management
- Michael Frank
  Chairman and CEO
- Carmelo Marrelli
  Chief Financial Officer
- Derrick Welsh
  Founder, Psilocin Pharma Corp.

Clinical
- Dr. Kelly McKee, Jr., MD, MPH
  Chief Scientific Officer, Consultant
- Dr. Onesmo Mpanju, PhD
  FDA Regulatory Affairs, Consultant

Board of Directors
- Michael Frank
  Chairman and CEO
- William Jackson
  Director
- Joshua Herman
  Director
- Christian Scovenna
  Director
- Andrew Lindzon
  Director
<table>
<thead>
<tr>
<th><strong>Ticker</strong></th>
<th>RVV (CSE)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Share Price</strong></td>
<td>CAD $0.195 (June 23, 2020)</td>
</tr>
<tr>
<td><strong>52 week High/Low</strong></td>
<td>CAD $0.38 / $0.025</td>
</tr>
<tr>
<td><strong>Capital Structure</strong></td>
<td>189,408,777 common shares (267,075,486 fully-diluted)</td>
</tr>
<tr>
<td><strong>Market Cap</strong></td>
<td>CAD ~ $37,000,000</td>
</tr>
</tbody>
</table>
Appendix – Bucillamine Scientific Rationale for COVID-19

Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficacy when not delivered early.1 This is because these drugs mostly act to prevent the early processes of virus binding to cells or viral replication.2 Thiols, particularly N-acetylcysteine (NAC), with antioxidant and reducing activity have been investigated as effective therapies that abrogate the potential for influenza to cause severe disease.3,4,5 Restoration of glutathione, the major intracellular thiol antioxidant, is a critical functional activity of NAC.6 Reactive oxygen species (ROS) generation during influenza virus infection aggravate destructive inflammation and programmed death of epithelial cells.7 Studies in human cells and animal models have shown that NAC works to prevent acute lung injury caused by influenza virus infection through inhibition of these ROS-mediated mechanisms.4,7 NAC has been investigated clinically and found to significantly attenuate clinical symptoms associated with influenza infection, especially in elderly at-risk patients.5 While NAC is easily taken up by cells and has low toxicity, clinical efficacy has required long-term and high-dose administration because of modest relative potency, limiting its clinical applicability.

Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.8 Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of Bucillamine as an intervention for COVID-19.
References


